Lemborexant
E2006
CAS Number: 1369764-02-2
Chemical Name: (1R, 2S) -2 – {[(2,4-dimethylpyrimidin-5-yl) oxy] methyl} -2- (3-fluorophenyl ) N (5-fluoropyridin-2-yl) cyclopropanecarboxamide
Indication: Insomnia
Company: Eisai
Synthesis coming…….watch out
References
- Christopher, John A (2014). “Small-molecule antagonists of the orexin receptors”. Pharmaceutical Patent Analyst 3 (6): 625–638.doi:10.4155/ppa.14.46. ISSN 2046-8954.
- Cristoph Boss, Catherine Ross (2015). “Recent Trends in Orexin Research – 2010 to 2015”. ScienceDirect.doi:10.1016/j.bmcl.2015.05.012.
- Boss, Christoph (2014). “Orexin receptor antagonists – a patent review (2010 to August 2014)”. Expert Opinion on Therapeutic Patents 24 (12): 1367–1381.doi:10.1517/13543776.2014.978859. ISSN 1354-3776.
- AdisInsight. “Lemborexant”. Springer. Retrieved 2015-05-23.
External links
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Registry Number | 1369764-02-2 |
| ATC code | None |
| PubChem | CID: 56944144 |
| ChemSpider | 34500836 |
| Chemical data | |
| Formula | C22H20F2N4O2 |
| Molecular mass | 410.417 g/mol |
////////
Filed under: Phase2 drugs, Uncategorized Tagged: Lemborexant
